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Cutaneous leishmaniasis: treatment 
options in young children 
This report of a Critically Appraised Topic (CAT) states that 
leishmaniasis is a heterogeneous disease classified accord-
ing to geographical region and extent of involvement (cuta-
neous, mucocutaneous, visceral). The authors explain that 
many treatment options are reported in the published litera-
ture for cutaneous leishmaniasis. These range from intrave-
nous infusions to locally destructive therapies; convention-
al treatment with pentavalent antimonials can be painful 
and may be associated with systemic side-effects. This CAT 
assessed oral miltefosine and topical paromomycin, two 
outpatient-based treatments, by appraisal of studies sup-
porting their use in the management of children with cuta-
neous leishmaniasis. The authors concluded that oral milt-
efosine, a new therapy that they used to treat a child with 
Leishmania tropica, is an effective treatment. They high-
lighted that current studies in cutaneous leishmaniasis are 
difficult to compare due to variation in study design and 
outcome measure(s); standardization of trials is needed. 
Br J Dermatol 2015; 172: 861-866
Propionibacterium species and 
follicular hyperkeratinization 
Jahns et al. set out to visualize directly the three major 
propionibacteria in control and acne skin samples. 
Additionally, they evaluated keratinocyte proliferation. 
Propionibacteria were visualized by immunol uores-
cence microscopy; keratinocyte proliferation was assessed 
by Ki67, keratin 16 (K16) and p63 immunochemistry. 
They reported that Propionibacteria acnes was identi-
fied in the majority of samples tested (n = 68, 48%), while 
P. granulosum was identified in only 12 samples (8%); 
P. avidum was not detected at all. Unexpectedly, acne sam-
ples did not show higher kera-
tinocyte proliferation than 
controls, nor was there any 
association between bacterial 
colonization and expression 
of Ki67/K16/p63. The authors 
concluded that their findings 
do not support earlier notions 
of follicular keratinocyte hyper-
proliferation as a cause of duc-
tal hypercornification in acne-
ic facial skin, and that further studies on the mechanisms 
underlying hypercornification in acne pathogenesis are now 
required. Br J Dermatol 2015; 172: 981-987
Myasthenia gravis, autoantibodies and 
paraneoplastic pemphigus 
This study by Wang et al. set out to investigate the symptoms, 
prognosis and profiles of associated autoantibodies in myas-
thenia gravis (MG), and their correlations in patients with 
paraneoplastic pemphigus (PNP). They assessed 58 patients 
with PNP for myasthenic symptoms and laboratory evidence 
of MG autoantibodies. Overall, 39% of the patients with PNP 
experienced muscle weakness, and 35% were diagnosed 
with MG. Moreover, 35% had positive antiacetylcholine 
receptor (anti-AChR) and 28% had antiacetylcholinesterase 
(anti-AChE) antibodies, similarly to patients with non-PNP 
MG (33% and 17%, respectively; P > 0.05). However, both 
were negative in all patients with pemphigus vulgaris, pem-
phigus foliaceus and connective tissue disorders, and healthy 
donors (P < 0.005). No other antibodies showed significant 
differences among groups. Anti-AChR and anti-AChE anti-
body levels were significantly increased in patients with PNP 
with dyspnoea, while anti-AChR, anti-titin and antiryanodine 
receptor antibodies were significantly increased in patients 
with PNP with muscle weakness (P < 0.05). The levels and 
positive rates of these autoantibodies showed no significant 
differences between PNP with Castleman disease and thy-
moma.  Although anti-AChE levels impacted survival dura-
tion (P = 0.027, odds ratio 3.14), MG complications did not 
affect the overall survival percentage in patients with PNP. 
The authors concluded that MG is a complication of PNP 
and that anti-AChR and anti-AChE antibodies are promi-
nent in patients with PNP, especially those with dyspnoea. 
Br J Dermatol 2015; 172: 968-975
Innovation in skin grafts for vitiligo 
The aim of this study was to compare two methods to cre-
ate fractional epidermal grafts. The authors explained that 
current treatments for vitiligo and chronic wounds are often 
not very effective. They noted that conventional epidermal 
blister grafting for chronic vitiligo is time consuming, is suit-
able only for small areas and requires surgical skill. Both of 
these two novel strategies yielded viable fractional epidermal 
microblister arrays, carried on a dressing for transfer to graft 
recipient sites. The microblisters were gradually released on 
hydration of the dressing adhesive. The authors concluded 
that one of these two methods, blister array, is practical for 
fractional epidermal micrografting to treat larger lesions with 
less donor-site trauma. They summarized the advantages of 
this method as follows: (i) simple automated harvesting and 
handling of the epidermal graft, (ii) the ability to treat a larger 
recipient skin area, (iii) rapid healing due to smaller blisters 
at the donor-site, and (iv) less donor-site trauma, potentially 
reducing the incidence of Koebner phenomenon, in which 
vitiligo is induced in sites of skin trauma. The authors state 
that prospective clinical trials for this innovative technology 
are now needed. Br J Dermatol 2015; 172: 1021-1028
